Skip to content

Creatine Supplementation in Pediatric Rheumatology

Efficacy and Safety of Creatine Supplementation in Patients With Juvenile Systemic Lupus Erythematosus and Juvenile Dermatomyositis

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01217320
Enrollment
40
Registered
2010-10-08
Start date
2011-01-31
Completion date
2012-09-30
Last updated
2012-01-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Juvenile Systemic Lupus Erythematosus, Juvenile Dermatomyositis

Keywords

rheumatology, creatine supplementation, quality of life, strength, juvenile systemic lupus erythematosus, juvenile dermatomyositis

Brief summary

Creatine supplementation may improve strength, muscle mass, bone mass and muscle function in healthy and elderly people. The investigators speculate that creatine supplementation could have therapeutic effects in pediatric rheumatic (i.e., juvenile systemic lupus erythematosus and juvenile dermatomyositis) patients who usually present muscle weakness, muscle wasting and bone mass loss.

Interventions

DIETARY_SUPPLEMENTcreatine

5g/d throughout 12 weeks

DIETARY_SUPPLEMENTplacebo (dextrose)

5g/d throughout 12 weeks

Sponsors

University of Sao Paulo
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
6 Years to 18 Years
Healthy volunteers
No

Inclusion criteria

* patients diagnosed with lupus systemic erythematosus and juvenile dermatomyositis * physically inactive * stable pharmacological treatment

Exclusion criteria

* macroalbuminuria * GFR \< 30 mL/min/1.73m2 * use of oral anticontraceptive agents * pregnancy * diabetes mellitus * hypothyroidism

Design outcomes

Primary

MeasureTime frame
muscle strengthafter six months

Secondary

MeasureTime frame
kidney function parametersafter six months
quality of lifeafter six months
muscle functionafter six months

Countries

Brazil

Contacts

Primary ContactBruno Gualano, PhD
gualano@usp.br551130913096

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 7, 2026